TNF-blockade in patients with advanced hormone refractory prostate cancer
نویسندگان
چکیده
منابع مشابه
Therapy for Advanced and Hormone Refractory Cancer of the Prostate
Cancers of the prostate are categorized as follows: 1)hormone-naive (never having previously received hormone manipulation); 2)androgen-dependent (having received hormonal manipulation but a less than continuous application, i.e., intermittent androgen blockade or with an agent that does not produce a castrate testosterone level, i.e., antiandrogen); 3)androgen independent (progressive disease ...
متن کاملManagement of patients with hormone refractory prostate cancer.
Prostate cancer is the second most common cancer in men in the UK, and the incidence of prostate cancer has increased dramatically over the past two decades. Although most men are diagnosed at early stage, more than 50% develop locally advanced or metastatic disease. Androgen ablation with luteinising hormone-releasing hormone (LHRH) agonists alone, or in combination with anti-androgens, is the...
متن کاملthe role of intermittent chemotherapy in the survival of patients with hormone refractory prostate cancer
introduction: prostate cancer is one of the most common cancers among males and the second factor resulting to death due to cancer among them.(1) the median age of its diagnosis is 65 years. the initial treatment includes androgen ablation or orchiectomy.(2, 3) in case of patient’s hormone refractory, chemotherapy would be substituted. the objective of this study is the consideration of intermi...
متن کاملPrognostic indicators in hormone refractory prostate cancer.
Prognostic factors in hormone refractory prostate cancer currently are of limited use to clinicians. Although studies have identified several factors that predict for poor survival in patients, most are either retrospective, or nonrandomized. Therefore, large prospective, randomized trials are needed to validate the significance of these factors. In addition, these indicators are largely descri...
متن کاملTherapeutic approach to hormone-refractory prostate cancer.
Over 60 years ago, Huggins and Hodges discovered androgen deprivation as an effective first-line therapy for metastatic prostate cancer. This leads to significant cancer control but in almost all men prostate cancer ultimately progresses to a hormone-refractory (HRPC) state resulting in significant morbidity and eventual death. In 2004, two landmark studies using docetaxel based chemotherapy de...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Investigational New Drugs
سال: 2009
ISSN: 0167-6997,1573-0646
DOI: 10.1007/s10637-009-9346-1